ConductScience.org, home

Paper30133478

Treatment of chronic hepatitis B naïve patients with a therapeutic vaccine containing HBs and HBc antigens (a randomized, open and treatment controlled phase III clinical trial).

Al Mahtab M and 8 others. PLoS One, 2018. Cited by 81 papers, by iCite.

Cite this record

ConductScience Library. Treatment of chronic hepatitis B naïve patients with a therapeutic vaccine containing HBs and HBc antigens (a randomized, open and treatment controlled phase III clinical trial). Papers, record 30133478. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/30133478

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Treatment of chronic hepatitis B naïve patients with a therapeutic vaccine containing HBs and HBc antigens (a randomized, open and treatment controlled phase III clinical trial).
PubMed
Journal
PLoS One
PubMed
Year
2018
PubMed
Publication types
Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
81
iCite
Relative citation ratio, by iCite
2.89
iCite
Revised in PubMed
2019-02-15
PubMed

Authors9

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Al Mahtab MMamun
2Akbar SMFSheikh Mohammad Fazlehttps://orcid.org/0000-0002-8139-2645
3Aguilar JCJulio Cesar
4Guillen GGerardo
5Penton EEuduaro
6Tuero AAngela
7Yoshida OOsamu
8Hiasa YYoichi
9Onji MMorikazu

Source PubMed

Download CSV of authors

Topics22

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Hepatitis B Core AntigensMajor topic
Hepatitis B Surface AntigensMajor topic
Hepatitis B, ChronicMajor topic
Adolescent
Adult
Antiviral Agents
Drug Therapy, Combination
Female
Hepatitis B Vaccines
Hepatitis B e Antigens
Hepatitis B virus
Humans
Interferon alpha-2
Interferon-alpha
Interferons
Male
Middle Aged
Polyethylene Glycols
Recombinant Proteins
Treatment Outcome
Vaccines
Viral Load

Source PubMed

Download CSV of topics

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT01374308NASVAC Phase-III Trial in Chronic Hepatitis B (CHB) PatientsDerived from the trialYes

Source ClinicalTrials.gov

Download CSV of trials

References24

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
124555998Anti-HBV DNA vaccination does not prevent relapse after discontinuation of analogues in the treatment of chronic hepatitis B: a randomised trial--ANRS HB02 VAC-ADN.Gut2015https://conductscience.org/library/papers/24555998PubMed
215589316Immunological characterization of two hepatitis B core antigen variants and their immunoenhancing effect on co-delivered hepatitis B surface antigen.Mol Immunol2005https://conductscience.org/library/papers/15589316PubMed
318596958A randomized controlled phase IIb trial of antigen-antibody immunogenic complex therapeutic vaccine in chronic hepatitis B patients.PLoS One2008https://conductscience.org/library/papers/18596958PubMed
425645624The royal wedding in chronic hepatitis B: The haves and the have-nots for the combination of pegylated interferon and nucleos(t)ide therapy.Hepatology2015https://conductscience.org/library/papers/25645624PubMed
510770795The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection.J Exp Med2000https://conductscience.org/library/papers/10770795PubMed
627210427Randomized phase II study of GS-4774 as a therapeutic vaccine in virally suppressed patients with chronic hepatitis B.J Hepatol2016https://conductscience.org/library/papers/27210427PubMed
720834101Immune modulator and antiviral potential of dendritic cells pulsed with both hepatitis B surface antigen and core antigen for treating chronic HBV infection.Antivir Ther2010https://conductscience.org/library/papers/20834101PubMed
818031872Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: a randomized, controlled study of co-administration of HBsAg/AS02 candidate vaccine and lamivudine.Vaccine2007https://conductscience.org/library/papers/18031872PubMed
922762143A pilot randomized controlled trial of dual-plasmid HBV DNA vaccine mediated by in vivo electroporation in chronic hepatitis B patients under lamivudine chemotherapy.J Viral Hepat2012https://conductscience.org/library/papers/22762143PubMed
1015660957Immunomodulatory therapy for chronic hepatitis B virus infection.Fundam Clin Pharmacol2005https://conductscience.org/library/papers/15660957PubMed
1117257877Phase I clinical trial in healthy adults of a nasal vaccine candidate containing recombinant hepatitis B surface and core antigens.Int J Infect Dis2007https://conductscience.org/library/papers/17257877PubMed
1226626120Novel insights into immunotherapy for hepatitis B patients.Expert Rev Gastroenterol Hepatol2016https://conductscience.org/library/papers/26626120PubMed
1320949114The Role of Interferon in Hepatitis B Therapy.Curr Hepat Rep2010https://conductscience.org/library/papers/20949114PubMed
1425132755Natural history of chronic hepatitis B: phases in a complex relationship.World J Gastroenterol2014https://conductscience.org/library/papers/25132755PubMed
1521682661Recent advances in the treatment of chronic hepatitis B.Expert Opin Pharmacother2011https://conductscience.org/library/papers/21682661PubMed
169185774Clearance of hepatitis B surface antigen after bone marrow transplantation: role of adoptive immunity transfer.Hepatology1997https://conductscience.org/library/papers/9185774PubMed
1719408969Management of chronic hepatitis B.Evid Rep Technol Assess (Full Rep)2008https://conductscience.org/library/papers/19408969PubMed
1826231459Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013.Lancet2015https://conductscience.org/library/papers/26231459PubMed
1919124812Antiviral therapy for adults with chronic hepatitis B: a systematic review for a National Institutes of Health Consensus Development Conference.Ann Intern Med2009https://conductscience.org/library/papers/19124812PubMed
2026202028Therapeutic potential of a combined hepatitis B virus surface and core antigen vaccine in patients with chronic hepatitis B.Hepatol Int2013https://conductscience.org/library/papers/26202028PubMed

See all 24 referencesDownload CSV of references

Cited by60

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 81 citations.

PMIDTitleJournalYearIn PapersSource
42798495Preventive and Therapeutic Vaccination for COVID-19 Using NASVAC.Euroasian J Hepatogastroenterol2026https://conductscience.org/library/papers/42798495PubMed
42797641Nucleos(t)ide Analog-Therapeutic Vaccination Switch: A Novel Approach for Safe and Effective Treatment Discontinuation in HBeAg (-) Chronic Hepatitis B Patients.Vaccines (Basel)2026https://conductscience.org/library/papers/42797641PubMed
42233029Emerging antiviral drugs and immunotherapy for chronic hepatitis B and associated liver disease.Front Immunol2026https://conductscience.org/library/papers/42233029PubMed
41757140The Sustainable Goal of Eliminating Hepatitis B, Functional Cure, and the Prospect of NASVAC: A Review.Euroasian J Hepatogastroenterol2025https://conductscience.org/library/papers/41757140PubMed
41746052EPIclip: A Novel Approach for the Production of Decorated Virus-Like Particles Mediated by High-Affinity Protein Binding Partners.Vaccines (Basel)2026https://conductscience.org/library/papers/41746052PubMed
41295547Hepatitis Vaccines: Recent Advances and Challenges.Vaccines (Basel)2025https://conductscience.org/library/papers/41295547PubMed
41149045Chronic Hepatitis B: Current Management and Future Directions.Diseases2025https://conductscience.org/library/papers/41149045PubMed
41014398Do the therapeutic vaccines hold hope for the treatment of hepatitis B?Hepatol Int2025https://conductscience.org/library/papers/41014398PubMed
40677768Canadian Association for the Study of the Liver Single Topic Conference on Hepatitis B Virus: 'Progress toward hepatitis B elimination in Canada'.Can Liver J2024https://conductscience.org/library/papers/40677768PubMed
40624334Identification of low-molecular compounds that inhibit envelope formation of hepatitis B virus.Sci Rep2025https://conductscience.org/library/papers/40624334PubMed
40528594[Research progress on new drugs for the treatment of chronic hepatitis B virus infection].Zhonghua Gan Zang Bing Za Zhi2025https://conductscience.org/library/papers/40528594PubMed
40212575Prevalence and Risk Factors of Significant Hepatic Fibrosis in Omani Patients with HBeAg-negative Chronic Hepatitis B Virus Infection: A Retrospective Study.Oman Med J2024https://conductscience.org/library/papers/40212575PubMed
39802853HeberNasvac: Development and Application in the Context of Chronic Hepatitis B.Euroasian J Hepatogastroenterol2024https://conductscience.org/library/papers/39802853PubMed
39717542Dysfunction and regulatory interplay of T and B cells in chronic hepatitis B: immunotherapy and emerging antiviral strategies.Front Cell Infect Microbiol2024https://conductscience.org/library/papers/39717542PubMed
38935536Harnessing CD8+ T cell dynamics in hepatitis B virus-associated liver diseases: Insights, therapies and future directions.Clin Transl Med2024https://conductscience.org/library/papers/38935536PubMed
38222949Impact of the Route and Schedule of Immunization on the Serological and Virological Response of Chronic Hepatitis B Patients Treated with HeberNasvac.Euroasian J Hepatogastroenterol2023https://conductscience.org/library/papers/38222949PubMed
38140265HBV Vaccines: Advances and Development.Vaccines (Basel)2023https://conductscience.org/library/papers/38140265PubMed
37539053Immune microenvironment changes of liver cirrhosis: emerging role of mesenchymal stromal cells.Front Immunol2023https://conductscience.org/library/papers/37539053PubMed
37509583Development of Therapy Based on the Exploration of Biological Events Underlying the Pathogenetic Mechanisms of Chronic Hepatitis B Infection.Biomedicines2023https://conductscience.org/library/papers/37509583PubMed
37243066Antiviral Response across Genotypes after Treatment of Chronic Hepatitis B Patients with the Therapeutic Vaccine NASVAC or Pegylated Interferon.Vaccines (Basel)2023https://conductscience.org/library/papers/37243066PubMed

See all 60 cited byDownload CSV of cited by

Genes5

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
GPT2875PubTator's text mininghttps://conductscience.org/library/genes/2875NCBI Gene
HBE13046PubTator's text mininghttps://conductscience.org/library/genes/3046NCBI Gene
IFNA13439PubTator's text mininghttps://conductscience.org/library/genes/3439NCBI Gene
IFNA23440PubTator's text mininghttps://conductscience.org/library/genes/3440NCBI Gene
KRT88P85348PubTator's text mininghttps://conductscience.org/library/genes/85348NCBI Gene

Download CSV of genes

Drugs2

The drugs whose trials, in the Pipelines release, list the paper.

DrugChEMBL IDThe trials list it asTrialsIn Drugs and targetsSource
INTERFERON ALFA-2BCHEMBL1201558Derived from the trial1https://conductscience.org/library/drugs/CHEMBL1201558ChEMBL
HEPATITIS B VIRUS HBSAG SURFACE PROTEIN ANTIGENCHEMBL4297973Derived from the trial1https://conductscience.org/library/drugs/CHEMBL4297973ChEMBL

Download CSV of drugs

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Comments and corrections
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/30133478

GET https://conductscience.org/api/papers/v1/30133478/references?page=2